ACVRL1 and chronic myelogenous leukemia, BCR-ABL1 positive: HHT is a protein translation inhibitor and induces apoptosis in AML cells with Mcl-1 downregulation, and it is approved for treatment of chronic myeloid leukemia resistant to BCR-ABL inhibitors [39, 40].